血清胸苷激酶1测定在体检人群癌变风险筛查中的意义

目的探讨血清胸苷激酶1（STK1）检测在体检人群癌变风险筛查中的应用价值。方法应用酶免疫点印迹化学发光法检测2 230例健康体检者STK1浓度,根据检测结果把体检者分为风险组（STK1〉2pmol/L）和正常组（STK1≤2pmol/L）,计算风险率,风险组和正常组比较采用两独立样本资料的t检验,分别对风险组和正常组人群结合其他检查结果和临床症状对其进行分析。结果风险组79例,STK1为2.03~17.25pmol/L,平均值（3.77±2.99）pmol/L,风险率为3.5%,其中恶性肿瘤5例,发生率为6.33%,良性疾病74例,占93.67%;正常组2 151例,STK1为0.10~2.00pmol/L,平均值（0.91±0.32）pmol/L,无恶性肿瘤病例;风险组和正常组之间STK1水平比较,差异有统计学意义（t=8.490,P〈0.01）;在风险组中,恶性肿瘤组的STK1水平明显高于良性疾病组（t=9.142,P〈0.01）。结论 STK1的水平与体内细胞增殖有良好的相关性,在恶性肿瘤的早期发现中有一定的应用价值,可作为一种新的肿瘤标志物应用于体检人群的癌变风险筛查。

The significance of serum thymidine kinase 1 in screening of cancer risk in physical examination people

Objective To evaluate the value of STK1in screening of cancer risk in physical examination people.Methods The concentrations of STK1were measured in 2 230cases of healthy people by enzyme immune chemiluminescence dot-blot assay.Healthy people were divided into risk group（STK1＆gt;2pmol/L）and normal group（STK1≤2pmol/L）based to the result of STK1 detection.Risk rate was calculated.Independent samples t-test was used for comparison of STK1level between risk group and normal group.People of risk group were tracked and the other inspection and clinical symptoms of them were analyzed.Results The value of STK1was 2.03-17.25（3.77±2.99）pmol/L in risk group（n=79）and 0.10-2.00（0.91±0.32）pmol/L in normal group（n=2 151）.The risk rate was 3.5%,Among the risk group,the occurring rate of malignant tumors in 5cases,6.33%,74cases of benign disease,accounting for 93.67%.There was statistical difference of STK1level between risk group and normal group（t=8.490,P＆lt;0.01）;In risk groups,the levels of STK1malignant tumor group was obviously higher than that of benign disease group and compared with benign disease group,has a very significant difference.Conclusion STK1level and body cell proliferation have good correlation,in the early detection of malignant tumors have certain application value,can be used as a new kind of tumor markers in the medical application of cancer risk screening.